drugset / Trial / NCT06904222
Safety and Immunogenicity of the Recombinant Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 18 Years and Older
RandomizedParallel-groupTriple-blindPrevention
Summary
This phase 1 study in China will evaluate the safety and immunogenicity of the the Respiratory Syncytial Virus (RSV) Vaccine, LYB005 in adults aged 18 years and older.
Timeline
- Start
- 2025-04-15
- Primary completion
- 2026-08
- Completion
- 2026-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | A01B | Unknown | — | — |
| Subject | LYB005 | Vaccine | 30 ug | — |
| Subject | LYB005 | Vaccine | 60 ug | — |
| Subject | LYB005 | Vaccine | 120 ug | — |